Antineoplastics
1
Reactions 1407 - 23 Jun 2012 S Antineoplastics Neutropenia and nausea: 5 case reports Three women and two men, aged 43–72 years, were identified from a study after they developed either neutropenia or nausea while receiving antineoplastics. The patients, who had been diagnosed with primary intraocular lymphoma, were initially treated with either intravitreal methotrexate or ocular radiotherapy. Four patients received intravitreal methotrexate 400µg injections once a week for 2 months, then once a month for 2 months. Five patients received five cycles of concurrent induction R-MPV chemotherapy, consisting of rituximab 375 mg/m 2 on day 1, methotrexate 3.5 g/m 2 and vincristine 1.4 mg/m 2 (maximum 2mg) on day 2, and procarbazine 100mg/m 2 /day for 7 days on odd-numbered cycles [routes not stated]. Patients then received prophylactic whole- brain radiotherapy. Systemic complications (grades 3–4) included four patients with neutropenia and one patient with nausea [durations of treatment to reaction onsets and outcomes not stated]; other adverse events included grades 1–2 mucositis. All patients subsequently achieved complete remission and were alive at last follow-up. Author comment: "The adverse events due to chemotherapy were grades 1–2 mucositis [patients not identified], vomiting, nausea, and grades 3–4 neutropenia." Taoka K, et al. Treatment of primary intraocular lymphoma with rituximab, high dose methotrexate, procarbazine, and vincristine chemotherapy, reduced whole- brain radiotherapy, and local ocular therapy. British Journal of Haematology 157: 252-254, No. 2, Apr 2012. Available from: URL: http://dx.doi.org/10.1111/ j.1365-2141.2011.08938.x - Japan 803072392 1 Reactions 23 Jun 2012 No. 1407 0114-9954/10/1407-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Transcript of Antineoplastics
Reactions 1407 - 23 Jun 2012
SAntineoplastics
Neutropenia and nausea: 5 case reportsThree women and two men, aged 43–72 years, were
identified from a study after they developed eitherneutropenia or nausea while receiving antineoplastics.
The patients, who had been diagnosed with primaryintraocular lymphoma, were initially treated with eitherintravitreal methotrexate or ocular radiotherapy. Fourpatients received intravitreal methotrexate 400µginjections once a week for 2 months, then once a month for2 months. Five patients received five cycles of concurrentinduction R-MPV chemotherapy, consisting of rituximab375 mg/m2 on day 1, methotrexate 3.5 g/m2 and vincristine1.4 mg/m2 (maximum 2mg) on day 2, and procarbazine100mg/m2/day for 7 days on odd-numbered cycles [routesnot stated]. Patients then received prophylactic whole-brain radiotherapy. Systemic complications (grades 3–4)included four patients with neutropenia and one patientwith nausea [durations of treatment to reaction onsets andoutcomes not stated]; other adverse events includedgrades 1–2 mucositis. All patients subsequently achievedcomplete remission and were alive at last follow-up.
Author comment: "The adverse events due tochemotherapy were grades 1–2 mucositis [patients notidentified], vomiting, nausea, and grades 3–4 neutropenia."Taoka K, et al. Treatment of primary intraocular lymphoma with rituximab, highdose methotrexate, procarbazine, and vincristine chemotherapy, reduced whole-brain radiotherapy, and local ocular therapy. British Journal of Haematology 157:252-254, No. 2, Apr 2012. Available from: URL: http://dx.doi.org/10.1111/j.1365-2141.2011.08938.x - Japan 803072392
1
Reactions 23 Jun 2012 No. 14070114-9954/10/1407-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
